Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH)’s share price hit a new 52-week high during trading on Wednesday . The company traded as high as $18.89 and last traded at $18.82, with a volume of 429,866 shares. The stock had previously closed at $18.34.

AMPH has been the subject of a number of recent research reports. Needham & Company LLC dropped their target price on Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, May 10th. Zacks Investment Research lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, July 28th. BMO Capital Markets began coverage on Amphastar Pharmaceuticals in a research note on Tuesday, June 28th. They set a “market perform” rating and a $17.00 price target for the company. Jefferies Group raised their price target on Amphastar Pharmaceuticals from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Tuesday, August 9th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and set a $22.00 price target on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 11th. Two analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $19.83.

The firm’s 50 day moving average price is $17.12 and its 200 day moving average price is $14.05. The stock has a market capitalization of $880.31 million and a price-to-earnings ratio of 63.34.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Monday, August 8th. The company reported $0.23 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.22. During the same period in the previous year, the company earned ($0.09) EPS. The firm had revenue of $68 million for the quarter, compared to analyst estimates of $62.10 million. Amphastar Pharmaceuticals’s revenue was up 26.4% compared to the same quarter last year. On average, equities research analysts predict that Amphastar Pharmaceuticals Inc. will post $0.37 earnings per share for the current year.

In other news, Director Richard K. Prins sold 7,500 shares of the company’s stock in a transaction that occurred on Monday, June 13th. The stock was sold at an average price of $15.94, for a total value of $119,550.00. Following the completion of the sale, the director now directly owns 29,086 shares in the company, valued at $463,630.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael A. Zasloff sold 48,375 shares of the company’s stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $18.15, for a total value of $878,006.25. Following the completion of the sale, the director now owns 42,792 shares of the company’s stock, valued at $776,674.80. The disclosure for this sale can be found here.

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.